IPP Bureau
Accenture invests in Ryght AI to revolutionize clinical trials
By IPP Bureau - December 16, 2025
Ryght AI tackles these hurdles with its AI Site Twin platform
FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission
By IPP Bureau - December 16, 2025
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary
By IPP Bureau - December 16, 2025
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
KIMS Hospital Bengaluru commences operations at PES University campus
By IPP Bureau - December 16, 2025
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Shelter Pharma launches D3 cure capsules
By IPP Bureau - December 16, 2025
This launch is part of the company's strategy to expand its nutraceutical portfolio
Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
By IPP Bureau - December 16, 2025
Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow
By IPP Bureau - December 16, 2025
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Pharma overhaul: EMA hails “Once-in-a-Generation” reform
By IPP Bureau - December 16, 2025
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis
By IPP Bureau - December 16, 2025
Sanofi secures two breakthrough nods in China for rare blood disorders
By IPP Bureau - December 16, 2025
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
By IPP Bureau - December 16, 2025
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline
By IPP Bureau - December 16, 2025
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
By IPP Bureau - December 16, 2025
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
By IPP Bureau - December 16, 2025
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
